Drug Profile


Alternative Names: RVX-000222; RVX-208

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Resverlogix Corporation
  • Class Anti-inflammatories; Cardiovascular therapies; Quinazolines; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acute coronary syndromes; Atherosclerosis; Low HDL cholesterol
  • Phase II Prediabetic-state
  • Phase I Alzheimer's disease
  • Preclinical Renal failure

Most Recent Events

  • 28 Jun 2017 Phase-III clinical trials in Acute coronary syndromes in Taiwan, Russia (PO)
  • 28 Jun 2017 Phase-III clinical trials in Low HDL cholesterol in Taiwan, Russia (PO)
  • 28 Jun 2017 Resverlogix receives fourth positive recommendation from Data Safety Monitoring Board for Apabetalone
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top